Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia.
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
06
05
2019
accepted:
28
10
2019
revised:
23
10
2019
pubmed:
9
11
2019
medline:
22
6
2021
entrez:
9
11
2019
Statut:
ppublish
Résumé
The purpose of our study is to provide information on safety and efficacy of ibrutinib as salvage treatment after allo-HSCT for CLL. A total of 56 patients were included, 36 (64%) males; median age at transplantation was 48 years (range: 35-64) and the median number of treatment lines prior to transplantation was 3 (1-10). The median time between allo-HSCT and Ibrutinib was 30 months (range: 1-140). Overall, 40 (71%) patients responded to Ibrutinib; 23 (41%) PR, and 17 (30%) CR. At time of ibrutinib initiation, ten patients had active chronic GVHD that resolved under Ibrutinib, whilst a single patient developed limited de novo chronic GVHD on Ibrutinib. Fourteen patients discontinued ibrutinib, four because of toxicity and ten because of disease progression. Overall, 14 patients progressed (median PFS = 24 months) among them 10 died. Two-year OS and PFS probabilities were 72% (95% CI: 52-84) and 50% (95% CI: 32-66), respectively. Patients with late relapse after allo-HSCT (≥24 months) had a better PFS after ibrutinib. Our study shows that ibrutinib can be safely administered for CLL relapse after allo-HSCT, with comparable efficacy to non-transplanted patients with high-risk disease.
Identifiants
pubmed: 31700137
doi: 10.1038/s41409-019-0742-7
pii: 10.1038/s41409-019-0742-7
doi:
Substances chimiques
Piperidines
0
ibrutinib
1X70OSD4VX
Adenine
JAC85A2161
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
884-890Références
Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32–42. https://doi.org/10.1056/NEJMoa1215637 .
doi: 10.1056/NEJMoa1215637
pubmed: 23782158
pmcid: 3772525
Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507–16. https://doi.org/10.1056/NEJMoa1306220 .
doi: 10.1056/NEJMoa1306220
pubmed: 23782157
pmcid: 4513941
Byrd JC, Brown JR, O’Brien S, Barrientos JC, Kay NE, Reddy NM, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371:213–23. https://doi.org/10.1056/NEJMoa1400376 .
doi: 10.1056/NEJMoa1400376
pubmed: 24881631
pmcid: 4134521
Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370:997–1007. https://doi.org/10.1056/NEJMoa1315226 .
doi: 10.1056/NEJMoa1315226
pubmed: 24450857
pmcid: 4161365
Mato AR, Nabhan C, Thompson MC, Lamanna N, Brander DM, Hill B, et al. Toxicities and outcomes of 621 ibrutinib-treated chronic lymphocytic leukemia patients in the United States: a real-world analysis. Haematologica. 2018. https://doi.org/10.3324/haematol.2017.182907 .
Coutre S, Choi M, Furman RR, Eradat H, Heffner L, Jones JA, et al. Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy. Blood. 2018. https://doi.org/10.1182/blood-2017-06-788133 .
Dreger P, Schetelig J, Andersen N, Corradini P, van Gelder M, Gribben J, et al. Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents? Blood. 2014;124:3841–9. https://doi.org/10.1182/blood-2014-07-586826 .
doi: 10.1182/blood-2014-07-586826
pubmed: 25301705
pmcid: 4276025
Michallet M, Sobh M, Milligan D, Morisset S, Niederwieser D, Koza V, et al. The impact of HLA matching on long-term transplant outcome after allogeneic hematopoietic stem cell transplantation for CLL: a retrospective study from the EBMT registry. Leukemia. 2010;24:1725–31. https://doi.org/10.1038/leu.2010.165 .
doi: 10.1038/leu.2010.165
pubmed: 20703257
Kramer I, Stilgenbauer S, Dietrich S, Bottcher S, Zeis M, Stadler M, et al. Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial. Blood. 2017;130:1477–80. https://doi.org/10.1182/blood-2017-04-775841 .
doi: 10.1182/blood-2017-04-775841
pubmed: 28716861
van Gelder M, de Wreede LC, Bornhauser M, Niederwieser D, Karas M, Anderson NS, et al. Long-term survival of patients with CLL after allogeneic transplantation: a report from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2017;52:372–80. https://doi.org/10.1038/bmt.2016.282 .
doi: 10.1038/bmt.2016.282
pubmed: 27941763
van Gelder M, Ziagkos D, de Wreede L, van Biezen A, Dreger P, Gramatzki M, et al. Baseline characteristics predicting very good outcome of allogeneic hematopoietic cell transplantation in young patients with high cytogenetic risk chronic lymphocytic leukemia - a retrospective analysis from the Chronic Malignancies Working Party of the EBMT. Clin Lymphoma Myeloma Leuk. 2017;17:667–75 e662. https://doi.org/10.1016/j.clml.2017.06.007 .
doi: 10.1016/j.clml.2017.06.007
pubmed: 28694085
Miklos D, Cutler CS, Arora M, Waller EK, Jagasia M, Pusic I, et al. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. Blood. 2017;130:2243–50. https://doi.org/10.1182/blood-2017-07-793786 .
doi: 10.1182/blood-2017-07-793786
pubmed: 28924018
pmcid: 6033048
Ryan CE, Sahaf B, Logan AC, O’Brien S, Byrd JC, Hillmen P, et al. Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. Blood. 2016;128:2899–908. https://doi.org/10.1182/blood-2016-06-715284 .
doi: 10.1182/blood-2016-06-715284
pubmed: 27802969
pmcid: 5179333
Kochenderfer JN, Dudley ME, Carpenter RO, Kassim SH, Rose JJ, Telford WG, et al. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood. 2013;122:4129–39. https://doi.org/10.1182/blood-2013-08-519413 .
doi: 10.1182/blood-2013-08-519413
pubmed: 24055823
pmcid: 3862276
Rozovski U, Benjamini O, Jain P, Thompson PA, Wierda WG, O’Brien S, et al. Outcomes of patients with chronic lymphocytic leukemia and richter’s transformation after transplantation failure. J Clin Oncol. 2015;33:1557–63. https://doi.org/10.1200/JCO.2014.58.6750 .
doi: 10.1200/JCO.2014.58.6750
pubmed: 25847930
pmcid: 4417727
Niemann CU, Herman SE, Maric I, Gomez-Rodriguez J, Biancotto A, Chang BY, et al. Disruption of in vivo chronic lymphocytic leukemia tumor-microenvironment interactions by ibrutinib–findings from an investigator-initiated Phase II study. Clin Cancer Res. 2016;22:1572–82. https://doi.org/10.1158/1078-0432.CCR-15-1965 .
doi: 10.1158/1078-0432.CCR-15-1965
pubmed: 26660519
Bachireddy P, Wu CJ. Arresting the inflammatory drive of chronic lymphocytic leukemia with ibrutinib. Clin Cancer Res. 2016;22:1547–9. https://doi.org/10.1158/1078-0432.CCR-15-3106 .
doi: 10.1158/1078-0432.CCR-15-3106
pubmed: 26847060
pmcid: 4818665
Inamoto Y, Fefer A, Sandmaier BM, Gooley TA, Warren EH, Petersdorf SH, et al. A phase I/II study of chemotherapy followed by donor lymphocyte infusion plus interleukin-2 for relapsed acute leukemia after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011;17:1308–15. https://doi.org/10.1016/j.bbmt.2011.01.004 .
doi: 10.1016/j.bbmt.2011.01.004
pubmed: 21232624
pmcid: 3123407
Schutt SD, Fu J, Nguyen H, Bastian D, Heinrichs J, Wu Y, et al. Inhibition of BTK and ITK with ibrutinib is effective in the prevention of chronic graft-versus-host disease in mice. PLoS One. 2015;10:e0137641. https://doi.org/10.1371/journal.pone.0137641 .
doi: 10.1371/journal.pone.0137641
pubmed: 26348529
pmcid: 4562702
Dubovsky JA, Flynn R, Du J, Harrington BK, Zhong Y, Kaffenberger B, et al. Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. J Clin Investig. 2014;124:4867–76. https://doi.org/10.1172/JCI75328 .
doi: 10.1172/JCI75328
pubmed: 25271622
Cameron F, Sanford M. Ibrutinib: first global approval. Drugs. 2014;74:263–71. https://doi.org/10.1007/s40265-014-0178-8 .
doi: 10.1007/s40265-014-0178-8
pubmed: 24464309
Kyle G. Chronic lymphocytic leukaemia and secondary skin malignancies. Br J Nurs. 2017;26:1026–32. https://doi.org/10.12968/bjon.2017.26.18.1026 .
doi: 10.12968/bjon.2017.26.18.1026
pubmed: 29034706
Richardson SE, Khan I, Rawstron A, Sudak J, Edwards N, Verfuerth S, et al. Risk-stratified adoptive cellular therapy following allogeneic hematopoietic stem cell transplantation for advanced chronic lymphocytic leukaemia. Br J Haematol. 2013;160:640–8. https://doi.org/10.1111/bjh.12197 .
doi: 10.1111/bjh.12197
pubmed: 23293871
Hahn M, Bottcher S, Dietrich S, Hegenbart U, Rieger M, Stadtherr P, et al. Allogeneic hematopoietic stem cell transplantation for poor-risk CLL: dissecting immune-modulating strategies for disease eradication and treatment of relapse. Bone Marrow Transplant. 2015;50:1279–85. https://doi.org/10.1038/bmt.2015.150 .
doi: 10.1038/bmt.2015.150
pubmed: 26146810
Mehta RS, Di Stasi A, Hosing C, Shah N, Rezvani K, Alousi A, et al. Lenalidomide-induced graft-vs.-Leukemia effect in a patient with chronic lymphocytic leukemia who relapsed after allogeneic stem cell transplant. Clin Lymphoma Myeloma Leuk. 2014;14:e105–109. https://doi.org/10.1016/j.clml.2013.12.013 .
doi: 10.1016/j.clml.2013.12.013
pubmed: 24502832
Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Loren AW, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015;7:303ra139. https://doi.org/10.1126/scitranslmed.aac5415 .
doi: 10.1126/scitranslmed.aac5415
pubmed: 26333935
pmcid: 5909068
Turtle CJ, Hay KA, Hanafi LA, Li D, Cherian S, Chen X, et al. Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-specific chimeric antigen receptor-modified T cells after failure of ibrutinib. J Clin Oncol. 2017;35:3010–20. https://doi.org/10.1200/JCO.2017.72.8519 .
doi: 10.1200/JCO.2017.72.8519
pubmed: 28715249
pmcid: 5590803